Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit

Journal of Pharmacological and Toxicological Methods

Volumn 63, Issue 1, 2011, Pages 40-46

  Jacobson, Ingemar ^a   Carlsson, Leif ^a   Duker, Göran ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

QT; QT interval prolongation; QT interval variability; Rabbit; Torsades de pointes

Indexed keywords

CALCIUM CHANNEL; DOFETILIDE; METHOXAMINE; SODIUM CHANNEL;

ANIMAL EXPERIMENT; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; HEART VENTRICLE ARRHYTHMIA; MALE; NONHUMAN; QT INTERVAL; QT PROLONGATION; RABBIT; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CELL LINE; ELECTROCARDIOGRAPHY; EMBRYO, MAMMALIAN; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HUMANS; ION CHANNELS; KIDNEY; LONG QT SYNDROME; MALE; METHOXAMINE; MODELS, STATISTICAL; PHENETHYLAMINES; RABBITS; RATS; SULFONAMIDES; TORSADES DE POINTES;

ORYCTOLAGUS CUNICULUS;

EID: 78650798799     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.04.010     Document Type: Article

References (30)

1. Amos G.J., Abrahamsson C., Duker G., Hondeghem L., Palmer M., Carlsson L. Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52 - Implications for proarrhythmic potential. Cardiovascular Research 2001, 49:351-360.
2. Andersson B., Abi-Gerges N., Carlsson L. The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability. Europace 2010, 12:1003-1010.
3. Bril A., Gout B., Bonhomme M., Landais L., Fiavre J.F., Linee P., et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. Journal of Pharmacology and Experimental Therapeutics 1996, 276:637-646.
4. Brown G.B. 3H-batrachotoxin-A-benzoate binding to voltage-sensitive sodium channels: Inhibition by the channel blockers tetrodotoxin and saxitoxin. Journal of Neuroscience 1986, 6:2064-2070.
5. Carlsson L. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacology & Therapeutics 2008, 119:160-167.
6. Carlsson L., Almgren O., Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit - Etiology and interventions. Journal of Cardiovascular Pharmacology 1990, 16:276-285.
7. Carlsson L., Amos G., Andersson B., Drews L., Duker G., Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride - Implications for proarrhythmic potential?. Journal of Pharmacology and Experimental Therapeutics 1997, 282:220-227.
8. Carlsson L., Andersson B., Linhardt G.S., Löfberg L. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential vs dofetilide in the methoxamine-sensitised rabbit in vivo. Journal of Cardiovascular Pharmacology 2009, 54:82-89.
9. Carlsson L., Drews L., Duker G., Schiller-Linhardt G. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anaesthetised rabbit. Journal of Pharmacology and Experimental Therapeutics 1993, 267:1076-1080.
10. Cheng C.S., Alderman D., Kwash J., Dessaint J., Patel R., Lescoe M.K., et al. A high throughput hERG potassium channel function assay: An old assay with a new look. Drug Development and Industrial Pharmacology 2002, 28:177-191.
11. Geller J.C., Egstrup K., Kulakowski P., Rosenqvist M., Aunes Jansson M., Berggren A., et al. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Journal of Clinical Pharmacology 2009, 49:312-322.
12. Hanton G., Yvon A., Racaud A. Temporal variability of QT interval and changes in T wave morphology in dogs as markers of the clinical risk of drug-induced proarrhythmia. Journal of Pharmacological and Toxicological Methods 2008, 57:194-201.
13. Hinterseer M., Thomsen M.B., Beckmann B., Pfeufer A., Schimpf R., Wichmann H.E., et al. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: A case control pilot study. European Heart Journal 2008, 29:185-190.
14. Hondeghem L., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic. Circulation 2001, 103:2004-2013.
15. Hondeghem L.M., Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. Journal of Cardiovascular Pharmacology 2003, 41:14-24.
16. Lengyel C., Varró A., Tábori K., Papp J.G., Baczkó I. Combined pharmacological block of IKr and IKs increases short-term QT interval variability and provokes torsades de pointes. British Journal of Pharmacology 2007, 151:941-951.
17. Michael G., Dempster J., Kane K.A., Coker S.J. Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation. British Journal of Pharmacology 2007, 152:1215-1227.
18. Orth P.M.R., Hesketh J.C., Mak C.K.H., Yang Y., Lin S., Beatch G.N., et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovascular Research 2006, 70:486-496.
19. Persson F., Carlsson L., Duker G. Blocking characteristics of hERG, hNav1.5 and hKvLQT1/hminK after administration of the novel antiarrhythmic compound AZD7009. Journal of Cardiovascular Electrophysiology 2005, 16:329-341.
20. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
21. Reynolds I.J., Snowman A.M., Snyder S.H. (-)[3 H)desmethoxy-verapamil labels multiple calcium channel modulators in brain and skeletal muscle membranes: Differentiation by temperature and dihydropyridine. Journal of Pharmacology and Experimental Therapeutics 1986, 237:731-738.
22. Scirica B.M., Morrow D.A., Hod H., Murphy S.A., Belardinelli L., Hedgepeth C.M., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome: Results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome - Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation 2007, 116:1647-1652.
23. Shah R.R., Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005, 2:758-772.
24. Svernhage E., Houltz B., Blomström P., Brachmann J., Crijns H., Jensen S., et al. Early electrocardiographic signs of drug-induced torsades de pointes. Annals of Noninvasive Electrophysiology 1998, 3:252-260.
25. Tang W., Kang J., Wu X., Rampe D., Wang L., Shen H., et al. Development and evaluation of high throughput functional assay methods for hERG potassium channel. Journal of Biomolecular Screening 2001, 6:325-331.
26. Thomsen M.B., Matz J., Volders P.G.A., Vos M.A. Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacology & Therapeutics 2006, 112:150-170.
27. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D.M., de Pater G., van Opstal J., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004, 10:2453-2459.
28. Vincze D., Farkas A.S., Rudas L., Makra P., Csík N., Leprán I., et al. Relevance of anaesthesia for dofetilide-induced torsades de pointes in α-adrenoceptor-stimulated rabbits. British Journal of Pharmacology 2008, 153:75-89.
29. Wang W.Q., Robertson C., Dhalla A.K., Belardinelli L. Antitorsadogenic effects of (±)-N-(2, 6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. Journal of Pharmacology and Experimental Therapeutics 2008, 325:875-881.
30. Wu Y., Carlsson L., Liu T., Yan G.X., Kowey P.R. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. Journal of Cardiovascular Electrophysiology 2005, 16:898-904.